Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer's Hemophilia A Portfolio Boosted by Jivi's EU Approval

Executive Summary

EU approval and coming launch there of Jivi will complement Bayer's two existing Factor VIII treatments, Kogenate and its successor Kovaltry.

You may also be interested in...



Roundup Lawsuits Overshadow Pharma Growth At Bayer

Pharmaceutical sales hit €4.35bn helped by a strong showing in China but as the number of glyphosate plaintiffs in the US jumps to 42,700, the German group's priority is sorting out Monsanto.

Analysts Weigh Up Benefits Of Big Bayer Restructuring

The investment community has praised Bayer's bosses for a "much-needed shake-up and slimming down of the organisation" as management increases its focus on the core pharmaceuticals business and looks to exit animal health.

Big Changes At Bayer With Animal Health Exit And 12,000 Jobs Cut

The German company is making some dramatic changes to its structure and in terms of pharma R&D, the focus will be very much on external alliances.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel